NCT01213407 2016-05-19
GBM-Vax
Activartis Biotech
Phase 2 Completed
Clinical Trials
6 trialsNCT00024570 2014-11-14
Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00089427 2011-07-04
IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma
INSYS Therapeutics Inc
Phase 1 Completed
NCT00024557 2011-06-06
Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients
INSYS Therapeutics Inc
Phase 1 Completed
NCT00041587 2011-06-06
Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma
INSYS Therapeutics Inc
Phase 1/2 Completed
NCT00076986 2011-06-06
The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme
INSYS Therapeutics Inc
Phase 3 Completed